Attached files

file filename
10-Q - FORM 10-Q - PHARMACEUTICAL PRODUCT DEVELOPMENT INCd10q.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex312.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex322.htm
EX-10.162 - SEVERANCE AGREEMENT - PHARMACEUTICAL PRODUCT DEVELOPMENT INCdex10162.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Pharmaceutical Product Development, Inc. (“PPD”) on Form 10-Q for the period ended March 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David L. Grange, Chief Executive Officer of PPD, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of PPD as of, and for, the periods presented in the Report.

Date: May 3, 2010

 

/s/ David L. Grange

David L. Grange
Chief Executive Officer